Therapeutic Effect of OK-432 for Lymphangioma in Children.
- Author:
Sung Eun JUNG
1
;
Dae Yeon KIM
;
In Bo SHIM
;
Seong Cheol LEE
;
Kwi Won PARK
;
Woo Ki KIM
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Lymphangioma;
OK-432
- MeSH:
Child*;
Fever;
Humans;
Inflammation;
Injections, Intralesional;
Lymphangioma*;
Lymphatic System;
Picibanil*;
Recurrence;
Streptococcus pyogenes
- From:Journal of the Korean Association of Pediatric Surgeons
1998;4(2):131-136
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lymphangioma is a congenital malformation of the lymphatic system that easily expands into surrounding tissue similar to malignancies. Surgical excision has been the treatment of choice, but the results of surgical resection have been unsatisfactory due to incomplete resection, fluid collection and recurrence after surgery. Intralesional injection of OK-432(lyophilized incubation mixture of group A. streptococcus pyogenes of human origin) was employed in treating 24 patients with lymphangiomas between 1992 and 1997. The therapy was used as a primary therapy in 21 patients. Also it used in 3 patients with unresectable or recurrent lymphangioma. The results of intralesional injection of OK-432 were excellent in 8 patients (33.3%), good in 7 patients (21.8%) and poor in 7 patients (21.8%). The side effects were fever under 39.0degrees C and a local inflammation, however, were subsided in a few days without serious complications. These data suggest that intralesional injection of OK-432 is safe and effective for lymphangioma as a primary therapy and unresectable or recurrent lymphangioma as a secondary therapy.
